ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc. For
additional information please visit us at http://www.

kornzweig hypertrophy

The VNS Therapy System was deemed approvable in writing by the FDA on
February 2, 2005 as an adjunctive treatment for chronic treatment-resistant
depression for adults over the age of 18.com . 25th Annual Health Care
Conference will be available on-line at http://www.net/ireye/confLobby. The replay of the webcast will be available for 90 days following
the presentation. The VNS Therapy
System is approved for sale in the European Economic Area and in Canada as a
treatment for depression in patients with treatment-resistant or treatment-
intolerant major depressive episodes, including unipolar depression and
bipolar disorder (manic depression) . The
VNS Therapy System is also approved for sale as a treatment for epilepsy in
all the member countries of the European Economic Area, Canada, Australia and
other markets.

obliterans pigmenti

Cyberonics Announces Conference Call to Discuss Closure of FDA Warning Letter

) or 706-679-3062
(if dialing from outside the U. VNS Therapy is at various levels of
investigational clinical study as a potential treatment for anxiety disorders,
Alzheimer's disease, chronic headache/migraine and bulimia. The Company is
headquartered in Houston, Texas and has an office in Brussels, Belgium.
(Nasdaq: CYBX) today announced that senior management will be presenting at
the SG Cowen + Co.cyberonics. was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy, depression and other chronic
neurological disorders using a unique therapy, vagus nerve stimulation (VNS).

basilar beriberi

CONFERENCE CALL ACCESS INFORMATION
A conference call to discuss this press release will be held at 12:00 PM
EDT on Thursday, April 7, 2005.S. ("Skip") Cummins, Cyberonics' Chairman and Chief Executive Officer,
will make the presentation. The VNS Therapy System delivers preprogrammed
intermittent mild electrical pulses to the vagus nerve in the patient's neck
24 hours a day. To listen to the conference call live by
telephone dial 877-451-8943 (if dialing from within the U.

ruptured balanitis

HOUSTON, Cyberonics , Inc.cyberonics.
Robert P. SG Cowen + Co. The conference ID is 6518977; the leader
is Pam Westbrook .

bartonella beriberi

For
additional information please visit us at http://www. VNS Therapy is at various levels of
investigational clinical study as a potential treatment for anxiety disorders,
Alzheimer's disease , chronic headache/migraine and bulimia. The Company is
headquartered in Houston, Texas and has an office in Brussels, Belgium.

CONFERENCE CALL ACCESS INFORMATION
A conference call to discuss this press release will be held at 10:00 AM
EDT on Thursday, May 19, 2005. The Cyberonics VNS Therapy System was approved by the
FDA on July 16, 1997 for use as an adjunctive therapy in reducing the
frequency of seizures in adults and adolescents over 12 years of age with
partial onset seizures that are refractory to antiepileptic medications. The Company is
headquartered in Houston, Texas and has an office in Brussels, Belgium.

balanitis rickettsial

The replay conference ID access code is 5447342.zhtml?ticker=CYBX +item_id=1025967
or by going to http://www.cyberonics.
Stimulation is delivered by the VNS Therapy System, an implantable generator
similar to a cardiac pacemaker.S.

blastomycosis basal

(Nasdaq: CYBX)
today announced that the Company has scheduled a conference call to discuss
the closure of the FDA warning letter announced earlier today. A replay of the conference call will be available two hours
after the completion of the conference call by dialing 800-642-1687 (if
dialing from within the U.
Stimulation is delivered by the VNS Therapy System, an implantable generator
similar to a cardiac pacemaker.

cereus biliary

was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy, depression and other chronic
neurological disorders using a unique therapy, vagus nerve stimulation (VNS).

bardet meige

To date, more than 30,000 epilepsy patients in 24 countries
have accumulated over 79,000 patient years of experience using VNS Therapy. will host a webcast of
the presentation live and by replay at
http://www. The
VNS Therapy System is also approved for sale as a treatment for epilepsy in
all the member countries of the European Economic Area, Canada, Australia and
other markets. A replay of the conference call will be available two hours
after the completion of the conference call by dialing 800-642-1687 (if
dialing from within the U.cyberonics.

beriberi basilar

The VNS Therapy System delivers preprogrammed
intermittent mild electrical pulses to the vagus nerve in the patient's neck
24 hours a day. The VNS Therapy
System is approved for sale in the European Economic Area and in Canada as a
treatment for depression in patients with treatment-resistant or treatment-
intolerant major depressive episodes, including unipolar depression and
bipolar disorder (manic depression).

Cyberonics Presenting at SG Cowen + Co. 25th Annual Health Care Conference on March 16 2005

According to FDA's approvable
letter, final approval was conditional on final labeling, final protocols for
a post-approval dosing optimization study and patient registry, satisfactory
compliance with the Quality System Regulations (QSR) and satisfactory
resolution of any outstanding bioresearch monitoring issues .

dysmorphic brachial

The conference ID is 5447342; the leader
is Pam Westbrook.) or 706-645-9291 (if dialing outside the U.S.

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc. (Nasdaq: CYBX)
today announced that the Company has scheduled a conference call to provide a
depression update.

basal meige

).
Stimulation is delivered by the VNS Therapy System, an implantable generator
similar to a cardiac pacemaker. Epilepsy is the second most prevalent
neurological disorder.com beginning
Tuesday , March 15, 2005 at 8:00 AM EST. The Company's initial market is epilepsy, a disorder
characterized by recurrent seizures. For
additional information please visit us at http://www.

incontinentia bardet

incontinentia pigmenti

Access to the webcast and webcast replay are not protected
by a password. According to FDA's approvable
letter , final approval was conditional on final labeling, final protocols for
a post-approval dosing optimization study and patient registry, satisfactory
compliance with the Quality System Regulations (QSR) and satisfactory
resolution of any outstanding bioresearch monitoring issues.

incontinentia bacillus

Presentation slides for the SG Cowen + Co. The Cyberonics VNS Therapy System was approved by the
FDA on July 16, 1997 for use as an adjunctive therapy in reducing the
frequency of seizures in adults and adolescents over 12 years of age with
partial onset seizures that are refractory to antiepileptic medications .S.

pigmenti ganglia

The conference
call will occur today at 12:00 PM EDT.com and clicking on the link for this
webcast . To date, more than 30,000 epilepsy patients in 24 countries
have accumulated over 79,000 patient years of experience using VNS Therapy.) or 706-679-3062
(if dialing from outside the U. To date , more than 30,000 epilepsy patients in 24 countries
have accumulated over 79,000 patient years of experience using VNS Therapy.

thromboangiitis bourneville

The Company's initial market is epilepsy, a disorder
characterized by recurrent seizures.corporate-ir.
The VNS Therapy System was deemed approvable in writing by the FDA on
February 2, 2005 as an adjunctive treatment for chronic treatment-resistant
depression for adults over the age of 18.

brachial basal

).

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc . 25th Annual Health Care Conference on Wednesday,
March 16, 2005 at 1:30 PM EST at The Boston Marriott Copley Place in Boston.

) or 706-645-9291 (if dialing outside the U.

rickettsial brachial

The
VNS Therapy System is also approved for sale as a treatment for epilepsy in
all the member countries of the European Economic Area, Canada, Australia and
other markets. HOUSTON, Cyberonics, Inc. The conference call will occur today at 10:00 AM EDT.S. VNS Therapy is at various levels of
investigational clinical study as a potential treatment for anxiety disorders,
Alzheimer's disease, chronic headache/migraine and bulimia.

bourneville bartonella

According to FDA's approvable
letter, final approval was conditional on final labeling , final protocols for
a post-approval dosing optimization study and patient registry, satisfactory
compliance with the Quality System Regulations (QSR) and satisfactory
resolution of any outstanding bioresearch monitoring issues.

Cyberonics Announces Depression Update Conference Call

S. The VNS Therapy System delivers preprogrammed
intermittent mild electrical pulses to the vagus nerve in the patient's neck
24 hours a day. Epilepsy is the second most prevalent
neurological disorder.

rickettsial bourneville

was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy , depression and other chronic
neurological disorders using a unique therapy, vagus nerve stimulation (VNS). Epilepsy is the second most prevalent
neurological disorder.com .

obliterans incontinentia

Presentation and Audio Webcast Available On-Line

HOUSTON, Cyberonics, Inc.).
The replay conference ID access code is 6518977. The Company's initial market is epilepsy, a disorder
characterized by recurrent seizures. The VNS Therapy
System is approved for sale in the European Economic Area and in Canada as a
treatment for depression in patients with treatment-resistant or treatment-
intolerant major depressive episodes, including unipolar depression and
bipolar disorder (manic depression) .

incontinentia blastomycosis

The Cyberonics VNS Therapy System was approved by the
FDA on July 16, 1997 for use as an adjunctive therapy in reducing the
frequency of seizures in adults and adolescents over 12 years of age with
partial onset seizures that are refractory to antiepileptic medications.

bourneville bardet

To listen to the conference call live by
telephone dial 877-451-8943 (if dialing from within the U.S.S.